Literature DB >> 1411649

Pulmonary toxicity of antineoplastic therapy.

H Kreisman1, N Wolkove.   

Abstract

Pulmonary toxicity is often encountered in patients receiving antineoplastic therapy. It may produce a wide variety of clinicopathologic syndromes. As new agents are introduced and their adverse effects recognized, clinicians should be ever vigilant about the possibility of pulmonary toxicity.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1411649

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  16 in total

Review 1.  Treating cancer patients. Practical monitoring and management of therapy-related complications.

Authors:  M Brigden; M McKenzie
Journal:  Can Fam Physician       Date:  2000-11       Impact factor: 3.275

2.  Neurocognitive function and CNS integrity in adult survivors of childhood Hodgkin lymphoma.

Authors:  Pinki K Prasad
Journal:  Transl Pediatr       Date:  2013-04

3.  Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study.

Authors:  Smita Bhatia; Liton Francisco; Andrea Carter; Can-Lan Sun; K Scott Baker; James G Gurney; Philip B McGlave; Auayporn Nademanee; Margaret O'Donnell; Norma K C Ramsay; Leslie L Robison; David Snyder; Anthony Stein; Stephen J Forman; Daniel J Weisdorf
Journal:  Blood       Date:  2007-08-01       Impact factor: 22.113

4.  Pulmonary toxicity after a quick course of combinatorial vincristine, bleomycin, and cisplatin neoadjuvant chemotherapy in cervical cancer.

Authors:  Kyung-Do Ki; Jong-Min Lee; Seon-Kyung Lee; Seo-Yun Tong; Chu-Yeop Huh; Jung-Kyu Ryu; Kyo-Young Kim
Journal:  J Korean Med Sci       Date:  2010-01-19       Impact factor: 2.153

5.  Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study.

Authors:  Smita Bhatia; Leslie L Robison; Liton Francisco; Andrea Carter; Yan Liu; Marcia Grant; K Scott Baker; Henry Fung; James G Gurney; Philip B McGlave; Auayporn Nademanee; Norma K C Ramsay; Anthony Stein; Daniel J Weisdorf; Stephen J Forman
Journal:  Blood       Date:  2005-02-08       Impact factor: 22.113

Review 6.  Risk-based health monitoring of childhood cancer survivors: a report from the Children's Oncology Group.

Authors:  Susan B Nunez; Daniel A Mulrooney; Caroline Laverdiere; Melissa M Hudson
Journal:  Curr Oncol Rep       Date:  2007-11       Impact factor: 5.075

7.  Yield of screening for long-term complications using the children's oncology group long-term follow-up guidelines.

Authors:  Wendy Landier; Saro H Armenian; Jin Lee; Ola Thomas; F Lennie Wong; Liton Francisco; Claudia Herrera; Clare Kasper; Karla D Wilson; Meghan Zomorodi; Smita Bhatia
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

Review 8.  Interstitial lung disease--an underdiagnosed side effect of chlorambucil?

Authors:  M Mohr; D Kingreen; H Rühl; D Huhn
Journal:  Ann Hematol       Date:  1993-12       Impact factor: 3.673

9.  Postoperative infections in immunocompromised patients after oncological surgery.

Authors:  J Y Ranchere; B Gordiani; P Bachmann
Journal:  Support Care Cancer       Date:  1995-11       Impact factor: 3.603

10.  Lung function changes after chemoradiation therapy in patients with lung cancer treated by three usual platinum combinations.

Authors:  Vasilios Mihailidis; Stavros Anevlavis; Georgia Karpathiou; George Kouliatsis; Argyrios Tzouvelekis; Paul Zarogoulidis; Paschalis Ntolios; Paschalis Steiropoulos; Demosthenes Bouros; Marios E Froudarakis
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.